标题
Current perspectives on bone metastases in castrate-resistant prostate cancer
作者
关键词
Castrate-resistant prostate cancer, Radium-223, Bone metastases, Tumor microenvironment
出版物
CANCER AND METASTASIS REVIEWS
Volume 37, Issue 1, Pages 189-196
出版商
Springer Nature
发表日期
2018-01-29
DOI
10.1007/s10555-017-9719-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prostate cancer: Cabozantinib activates innate immunity
- (2017) Peter Sidaway Nature Reviews Urology
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Alteration of osteoblast arrangement via direct attack by cancer cells: New insights into bone metastasis
- (2017) Yumi Kimura et al. Scientific Reports
- Stromal factors involved in human prostate cancer development, progression and castration resistance
- (2016) Noemi Eiro et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
- (2016) Fred Saad et al. LANCET ONCOLOGY
- Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223
- (2016) Andrea K. Miyahira et al. PROSTATE
- Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223
- (2016) Robert Coleman SEMINARS IN NUCLEAR MEDICINE
- Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX
- (2016) Domenica Rea et al. Biomed Research International
- From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases
- (2016) Knut Liepe et al. Therapeutic Advances in Medical Oncology
- The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone
- (2015) Pierrick G.J. Fournier et al. CANCER CELL
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
- (2015) A. Varkaris et al. CLINICAL CANCER RESEARCH
- Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
- (2015) Ethan M. Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
- (2015) Matthew Raymond Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis
- (2015) Diane S. Abou et al. JNCI-Journal of the National Cancer Institute
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis
- (2015) Diane S. Abou et al. JNCI-Journal of the National Cancer Institute
- Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
- (2014) P. D. Ottewell et al. ENDOCRINE-RELATED CANCER
- Prostate Cancer Cells Preferentially Home to Osteoblast-rich Areas in the Early Stages of Bone Metastasis: Evidence From In Vivo Models
- (2014) Ning Wang et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases
- (2014) X. Wan et al. Science Translational Medicine
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Fighting Prostate Cancer with Radium-223 — Not Your Madame's Isotope
- (2013) Neha Vapiwala et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer
- (2013) C. J. Logothetis et al. Cancer Discovery
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- A bone marrow toxicity model for223Ra alpha-emitter radiopharmaceutical therapy
- (2012) Robert F Hobbs et al. PHYSICS IN MEDICINE AND BIOLOGY
- Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
- (2011) V. Tzelepi et al. CLINICAL CANCER RESEARCH
- Steps in prostate cancer progression that lead to bone metastasis
- (2011) Jung-Kang Jin et al. INTERNATIONAL JOURNAL OF CANCER
- Accurate Description of the Cell Survival and Biological Effect at Low and High Doses and LET's
- (2011) Anders BRAHME JOURNAL OF RADIATION RESEARCH
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
- (2011) F. Dayyani et al. JNCI-Journal of the National Cancer Institute
- A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
- (2011) M. Hidalgo et al. MOLECULAR CANCER THERAPEUTICS
- Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms
- (2008) Zhi Gang Li et al. JOURNAL OF CLINICAL INVESTIGATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started